We Offer Worldwide Shipping
Login Wishlist

Lentinan

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-L2014

  • Specification : 98%

  • CAS number : 37339-90-5

  • Formula : C42H72O36

  • Molecular Weight : 1153.002

  • PUBCHEM ID : 37723

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-L2014

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

1153.002

Appearance

Powder

Botanical Source

Shiitake

Structure Type

Carbohydrates

Category

Standards;Natural Pytochemical;API

SMILES

C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)OC3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)CO)O)OC5C(C(C(C(O5)COC6C(C(C(C(O6)CO)O)O)O)O)OC7C(C(C(C(O7)CO)O)O)O)O)O)O)O)O)O)O)O

Synonyms

Biomoduline/D-allo-Heptitol, O-α-D-glucopyranosyl-(1->6)-O-[O-α-L-glucopyranosyl-(1->6)-O-[3-O-methyl-β-D-glucopyranosyl-(1->3)]-O-β-D-allopyranosyl-(1->;3)-β-D-allopyranosyl-(1->3)]-O-β-D-allo pyranosyl-(1->4)-2,6-anhydro-7-deoxy-, (6ξ)-/α-D-Glucopyranosyl-(1->6)-[α-L-glucopyranosyl-(1->6)-[3-O-methyl-β-D-glucopyranosyl-(1->3)]-β-D-allopyranosyl-(1->3)-β-D-allopyranosyl-(1->3)]-β-D-allopyranosyl-(1->4)-2,6-anhydro- 6-methyl-D-allitol

IUPAC Name

(2R,3R,4S,5S,6R)-2-[[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5,6-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Density

1.8±0.1 g/cm3

Solubility

Flash Point

823.2±34.3 °C

Boiling Point

1437.5±65.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:37339-90-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

30043277

Abstract

PURPOSE:
Lentinan is a polysaccharide extracted from Shiitake mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.

METHODS:
We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.

RESULTS:
The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [p < 0.001, 95% confidence interval (CI) 0.102-0.170]. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI 0.74-0.85) and no statistical heterogeneity was found among studies (I2 = 11%).

CONCLUSION:
Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.

KEYWORDS

Cancer; Chemotherapy; Immunobalance; Immunostimulant; Lentinan

Title

Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China.

Author

Zhang Y1, Zhang M1, Jiang Y1,2, Li X1,2, He Y1,2, Zeng P1, Guo Z2, Chang Y1,2, Luo H1,2, Liu Y1,2, Hao C1, Wang H1, Zhang G1, Zhang L3.

Publish date

2018 Nov

PMID

30373628

Abstract

BACKGROUND:
Antiangiogenic agents are commonly used in lung and colon cancer treatments, however, rapid development of drug resistance limits their efficacy.

METHODS:
Lentinan (LNT) is a biologically active compound extracted from Lentinus edodes. The effects of LNT on tumor angiogenesis were evaluated by immunohistochemistry in murine LAP0297 lung and CT26 colorectal tumor models. The impacts of LNT on immune cells and gene expression in tumor tissues were determined by flow cytometry, qPCR, and ELISA. Nude mice and IFNγ blockade were used to investigate the mechanism of LNT affecting on tumor angiogenesis. The data sets were compared using two-tailed student’s t tests or ANOVA.

RESULTS:
We found that LNT inhibited tumor angiogenesis and the growth of lung and colon cancers. LNT treatments elevated the expression of angiostatic factors such as IFNγ and also increased tumor infiltration of IFNγ-expressing T cells and myeloid cells. Interestingly, IFNγ blockade, but not T cell deficiency, reversed the effects of LNT treatments on tumor blood vessels. Moreover, long-lasting LNT administration persistently suppressed tumor angiogenesis and inhibited tumor growth.

CONCLUSIONS:
LNT inhibits tumor angiogenesis by increasing IFNγ production and in a T cell-independent manner. Our findings suggest that LNT could be developed as a new antiangiogenic agent for long-term treatment of lung and colon cancers.

KEYWORDS

Antiangiogenic therapy; Drug resistance; Interferon γ; Lentinan; Lung cancer

Title

Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner.

Author

Deng S1, Zhang G2, Kuai J1, Fan P1, Wang X1, Zhou P1, Yang D3, Zheng X1, Liu X1, Wu Q4, Huang Y5.

Publish date

2018 Oct 29

PMID

31581847

Abstract

Myocardial ischemia is a serious disease which threatens human’s life. Lentinan (LEN) possesses multiple biological properties: anticancer, antibacterial, antiviral and antioxidant effects. Our study investigated the effects of LEN on hypoxia-stimulated cardiomyocytes and the underlying mechanism. Primary neonatal rat ventricular cardiomyocytes (PNCM) were isolated from neonate rat pups. PNCM and H9c2 cells were stimulated by hypoxia and treated by LEN. Cell viability and apoptosis were detected by cell counting kit-8 and flow cytometry, respectively. Moreover, apoptotic factors were examined by western blot. Phosphatidylinositol 3′-kinase (PI3K)/protein kinase B (AKT) and β-catenin pathways related proteins were analyzed by western blot. Furthermore, the expression of microRNA-22 (miR-22) was detected by qRT-PCR. Altered expression of miR-22 and silenced information regulator 1 (Sirt1) was achieved by transfection. The relationship between miR-22 and Sirt1 was verified by luciferase assay. We found that LEN promoted cell viability and decreased apoptosis which led to the contrary results with what hypoxia induced. Moreover, LEN decreased the ratio of Bax to Bcl-2 and the level of cleaved caspase-3, as well as activated PI3K/AKT and β-catenin. LEN decreased the expression of miR-22 which was upregulated by hypoxia. miR-22 overexpression broken the promoting effects led by LEN. Moreover, Sirt1 was verified to be a target of miR-22. Silence of Sirt1 led to the opposite results with LEN. In conclusion, LEN relieved hypoxia-induced cellular injuries evidenced by increasing viability and decreasing apoptosis via down-regulation of miR-22, which was accompanied by activation of PI3K/AKT and β-catenin pathways. Highlights Lentinan alleviates hypoxia-induced injuries of PNCM and H9c2 cells; microRNA-22 expression is decreased by lentinan; Lentinan reduces hypoxia-induced injury by microRNA-22 downregulation; Lentinan regulates PI3K/AKT and Wnt/β-catenin by regulation of microRNA-22/Sirt1.

KEYWORDS

Myocardial ischemia; PI3K/AKT; lentinan; microRNA-22; β-catenin

Title

Lentinan protects cardiomyocytes against hypoxia-induced injury by regulation of microRNA-22/Sirt1.

Author

Zhang S1, Zhao Y2.

Publish date

2019 Dec


Description :

Empty ...